Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Conclusion: Response to acalabrutinib remained consistent during long-term (>24-month) follow-up, including high response rates, median PFS of 19.5 months, and a median OS that has not yet been reached, confirming efficacy in patients with relapsed/refractory MCL. The AE profile was largely similar to earlier reporting, with limited additional safety events observed with an additional year of follow-up.DisclosuresWang: Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Dava Oncology: Honoraria; AstraZeneca: Consultancy, Research Funding; Pharmacyclics: Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Juno: Research Funding; MoreHealth: Consultancy; Acerta Pharma: Honoraria, Research Funding; Kite Pharma: Research Funding; Novartis: Research Funding. Rule: Celltrion: Membership on an entity's Board of Directors or advisory committees; Gilead Sciences, Inc.: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Roche: Honoraria; Kite: Membership on an entity's Board of Directors or advisory committees. Zinzani: Roche: Honoraria, Membership on an entity's Board of Directo...
Source: Blood - Category: Hematology Authors: Wang, M., Rule, S., Zinzani, P. L., Goy, A., Casasnovas, O., Smith, S. D., Damaj, G., Doorduijn, J. K., Lamy, T., Morschhauser, F., Panizo, C., Shah, B. D., Davies, A., Eek, R., Dupuis, J., Jacobsen, E., Kater, A. P., LE Gouill, S., Oberic, L., Robak, T., Tags: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma-Clinical Studies: Poster II Source Type: research
More News: Anemia | Aortic Stenosis | AstraZeneca | Bleeding | Cancer | Cancer & Oncology | Cardiology | Cough | Coumadin | Cytomegalovirus | Depression | Employment | European Medicines Agency (EMA) | Gastroenterology | Genetics | Headache | Heart | Heart Attack | Hodgkin's Disease | Hypertension | Lung Cancer | Lymphoma | Merck | Migraine | Myelodysplastic Syndrome | Nanotechnology | Non-Hodgkin's Lymphoma | Non-Small Cell Lung Cancer | Oral Cancer | Pfizer | Pharmaceuticals | Pneumonia | Pulmonary Thromboembolism | Study | Suicide | Toxicology | Vitamin K | Vitamins | Warfarin